课题基金 / 基金详情

Characterizing and validating diacetylspermine as a metabolic biomarker of drug response and precision treatment in triple-negative breast cancer

Characterizing and validating diacetylspermine as a metabolic biomarker of drug response and precision treatment in triple-negative breast cancer
表征和验证二乙酰精胺作为三阴性乳腺癌药物反应和精准治疗的代谢生物标志物
批准号：
472346
负责人：
Velenosi Thomas J
金额：
$7.29万
依托单位：
University of British Columbia
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
已结题
起止时间：
2022-09-01 至 2023-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=472346&lang=en
关键词：
Biomarkers Diacetylspermine Patient-Derived Xenografts Polaymines Spermine/Spermidine N1-Acetyltransferase 1 Triple Negative Breast Cancer

项目摘要

项目成果

Velenosi Thomas J的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Triple-negative breast cancer (TNBC) is the deadliest breast cancer subtype, in part due to lack of targeted therapy. Therefore, there is a need to improve methods that determine if treatment is effective and to develop targeted therapies. Cancer cells re
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Characterizing diacetylspermine as a biomarker of drug response and precision treatment in triple-negative breast cancer
  • 批准号：
    494927
  • 项目类别：
    Operating Grants
  • 资助金额：
    $7.29万
  • 财政年份：
    2023
  • 负责人：
    Velenosi Thomas J
  • 依托单位：
    University of British Columbia
Metabolic signatures of triple negative breast cancer sensitivity and resistance to cyclophosphamide and doxorubicin in patient derived tumor xenografts
海外基金